FBLG — FibroBiologics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1958777 ·
Last close
$1.11
Market Cap
$7.39M
52W High
$10.28
52W Low
$0.62
ADV30
228,912
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,033,000 | -4,117,000 | 7,929,000 | 3,515,000 | 3,293,000 |
| Mar 2026 | 0 | — | -5,068,000 | -5,000,000 | 5,938,000 | 1,482,000 | 3,338,000 |
| Dec 2025 | 0 | — | -2,590,000 | -3,244,000 | 9,619,000 | 4,894,000 | 3,463,000 |
| Sep 2025 | 0 | — | -5,038,000 | -5,778,000 | 8,744,000 | 4,867,000 | 8,619,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,483,000
Investing CF
$-219,000
Financing CF
$8,517,000
CapEx
$-361,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.04
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-59,164,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-18,472,000
Pretax Income TTM
$-18,680,000
Interest Exp TTM
$208,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,649,000 | -18,646,000 | 9,619,000 | 3,463,000 | 6,156,000 | -16,394,000 |
| Dec 2024 | 0 | -13,737,000 | -11,161,000 | 16,445,000 | 13,710,000 | 2,735,000 | -11,901,000 |
| Dec 2023 | 0 | -8,889,000 | -16,485,000 | 11,821,000 | 10,568,000 | 1,253,000 | -6,401,000 |
| Dec 2022 | 0 | -4,467,000 | -5,121,000 | 4,824,000 | 8,820,000 | -3,996,000 | -4,066,000 |
TTM Snapshot
Revenues TTM
$168,000
NetIncome TTM
$-18,680,000
OpCashFlow TTM
—
Assets (Latest)
$5,938,000
Forward EPS
$-3.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRAW | Traws Pharma, Inc. | $7.38M | $0.48 | — |
| SKYE | Skye Bioscience, Inc. | $7.44M | $1.68 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.46M | $4.76 | — |
| INM | InMed Pharmaceuticals Inc. | $7.31M | $1.33 | — |
| SNGX | SOLIGENIX, INC. | $7.54M | $0.35 | — |
News headlines (Yahoo Finance, 1h cache)
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
2026-10-07 12:30 · Yahoo
EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections
2026-10-07 12:15 · Yahoo
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
2026-09-29 12:30 · Yahoo
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
2026-09-17 12:30 · Yahoo
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
2026-09-08 13:00 · Yahoo
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
2026-09-01 12:30 · Yahoo
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
2026-08-27 12:30 · Yahoo
FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia
2026-08-27 08:25 · Yahoo
FibroBiologics Regains Compliance with Nasdaq Trading Rules
2026-08-26 12:30 · Yahoo
FibroBiologics Appoints Leigh Steinberg to Board of Directors
2026-08-24 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.